A Phase 1/2a study of a candidate factor replacement therapy BIVV001 in adults with severe haemophilia A has shown significant levels of factor activity. The results were published on 10 September in The New England Journal of Medicine. The developer is Swedish Orphan Biovitrum AB which is collaborating with Sanofi SA on the programme.
Haemophilia A is an inherited bleeding disorder in which the blood does not clot properly. It is caused by a lack, or a decrease, of clotting Factor 8.